Testosterone > ng/dL within days prior to Step registration Serum testosterone concentration ? ng/dL sustained by medical or surgical castration Parts A,B or D (TNBC) Serum testosterone concentration ? ng/dL sustained by medical or surgical castration. Serum testosterone < ng/dL Currently taking testosterone, methyltestosterone, oxandrolone (Oxandrin), oxymetholone, danazol, fluoxymesterone (Halotestin), or testosterone-like agents. Serum testosterone level < ng/mL Serum testosterone ? ng/dL Testosterone level =< ng/dL Serum testosterone < ng/ml Screening serum testosterone > ng/dL Be surgically or medically castrated, with serum testosterone levels of ? ng/dL (. nM) Testosterone level < ng/dL Patient may have had prior neoadjuvant and/or adjuvant therapy (chemotherapy, vaccines or experimental agents) within weeks prior to randomization, if the PSA rise and PSADT were documented after the testosterone level was > ng/dL Patient must have hormone-sensitive prostate cancer as evident by a serum total testosterone level > ng/dL within weeks prior to randomization Serum testosterone level < ng/dL at screening Testosterone =< ng/dL Not a candidate for standard effective therapy NOTE: In men with prostate cancer, baseline testosterone levels must also be ?ng/dL (? .nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study. Serum testosterone of ng/dL or greater (if initial T is < it can be repeated [recommended before AM] and if > patient will be considered eligible). If patient was on testosterone supplementation, testosterone measurements need to be obtained > weeks off supplements Serum testosterone > ng/mL Serum testosterone level =< ng/dL at the screening visit Baseline testosterone >= ng/dl Testosterone level ? ng/dL Asymptomatic or symptomatic hormone naive men with testosterone levels >= ng/dL with previously treated localized prostate cancer who now have rising PSAs and five or fewer bone metastases Men with baseline serum testosterone < ng/dL Serum testosterone > ng/dL. For patients treated up to month of LHRH agonist, a testosterone measurement prior to the LHRH treatment will be used to determine eligibility, and must have been > ng/dL. If no testosterone level is available from before LHRHa injection up to days prior to study entry, the patient will be ineligible. Surgically or ongoing medically castrated, with baseline testosterone levels of =< ng/dL =< . nM). Eugonadal state (serum testosterone > ng/dL). Serum testosterone >= ng/dl Baseline testosterone > ng/dL if patient has not initiated hormonal therapy; for those patients who have already initiated hormonal therapy, baseline testosterone is not required Serum testosterone >= ng/dL Serum testosterone >= ng/dL Surgically or ongoing medically castrated, with baseline testosterone levels of =< ng/dL (=< . nM) Requires estrogen or testosterone Ongoing androgen deprivation with serum testosterone < ng/dl Patients may be receiving continuous hormonal ablation with surgical or medical castration with baseline testosterone < ng/dL Serum testosterone >= ng/dL Bilirubin < . ng/dl Creatinine < . ng/dl Serum testosterone levels < ng/L after surgical or continued chemical castration Patients must have ongoing therapy to maintain serum testosterone < ng/dL Androgens (testosterone, dihydroepiandrosterone, etc.); Known castrate-resistant disease with serum testosterone level less than or equal to (= ng/dL Baseline testosterone >= ng/dl Serum testosterone levels less than (<) nanogram per deciliter (ng/dL) determined within weeks prior to start of study drug Patients must have a serum total testosterone level >= ng/dL at the time of enrollment within weeks prior to randomization Hypogonadism or severe androgen deficiency as defined by screening serum testosterone < ng/dL Surgically or medically castrated, with testosterone levels of less than (<) nanogram per deciliter (ng/dL) Hypogonadism or severe androgen deficiency as defined by screening serum testosterone less than ng/dL below the normal range for the institution Participants must have a testosterone level < ng/dL Participants must have a testosterone levels < ng/dL Testosterone >= ng/dL per laboratory reference range Testosterone < ng/dL Serum testosterone > ng/dL at study entry Patients must have a serum testosterone of ng/dL or greater Ongoing androgen blockade demonstrated by serum testosterone concentration of less than ng/dL Total testosterone < ng/ml, except in patients with prior orchiectomy, where testosterone does not need to be measured; patients must continue their LHRH agonist therapy throughout study duration Serum testosterone at screening < ng/dL Serum testosterone >= ng/dL determined within months prior to enrollment Prior orchiectomy or serum testosterone levels < ng/dL determined within weeks prior to start of study drug. Serum testosterone level < ng/dL at Screening visit Serum testosterone levels < ng/ml Serum testosterone level < ng/dL Castrate levels of serum testosterone (=< ng/dL or . mmol/L) confirmed within two weeks prior to day of treatment; testosterone levels will not be required for patients who have had bilateral orchiectomy Testosterone < ng/dL; patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy Serum testosterone < ng/dL determined within weeks of first administration of study drug Effective castration (serum testosterone levels ?. ng/mL). Serum testosterone (total) less than ng/ml at time of enrollment Patients with pure small cell neuroendocrine carcinoma on histology are not required to have received prior androgen deprivation therapy (ADT) or castrate levels of testosterone, but their testosterone state should be maintained for the duration of the study. Other patients are required to have surgical or ongoing chemical castration, with baseline testosterone level ng/dL between these two successive measurements Patients with hypogonadism or severe androgen deficiency as defined by serum testosterone less than ng/dL will not be eligible Serum testosterone < nanogram per deciliter (ng/dL) (. nanomole per liter [nM/L]) Surgical or medical castration with testosterone less than ng/dL Serum testosterone levels < ng/dL Medical or surgical castration with testosterone less than ng/dL Eugonadal state (serum testosterone > ng/dL) Serum testosterone, measured by liquid chromatography (LC)mass spectrometry (MS)/MS, < ng/dL and/or calculated free testosterone < pg/mL Baseline hypogonadism as defined as a testosterone < ng/dL Hypogonadism or severe androgen deficiency as defined by screening serum testosterone < ng/dL Serum testosterone =< ng/dL Serum testosterone < ng/dL determined within weeks of first administration of study drug Patients may be receiving continuous hormonal ablation with surgical or medical castration with baseline testosterone < ng/dL Metastatic disease that has progressed despite castrate levels of testosterone (surgically or medically castrated, with testosterone levels of < ng/dL) SUB-STUDY III: Castrate-levels of testosterone (total testosterone < ng/dL) Patients must have testosterone levels >= ng/dL Ongoing androgen deprivation with serum testosterone < ng/dL (< . nM) Patients receiving testosterone supplementation Testosterone levels ? ng/dL Must continue ongoing androgen deprivation therapy with castrate levels of serum testosterone < nanogram/deciliter (ng/dL)